Hiromi Shimada1, Tomohiro Kameda2, Kenji Kanenishi3, Nobuyuki Miyatake4, Shusaku Nakashima2, Risa Wakiya2, Mikiya Kato2, Taichi Miyagi2, Mai Mahmoud Fahmy Mansour2, Toshiyuki Hata3, Norimitsu Kadowaki2, Hiroaki Dobashi2. 1. Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, 1750-1, Ikenobe, Miki-cho, Kita-gun, Kagawa, 761-0793, Japan. h_kizu@med.kagawa-u.ac.jp. 2. Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, 1750-1, Ikenobe, Miki-cho, Kita-gun, Kagawa, 761-0793, Japan. 3. Department of Perinatology and Gynecology, Faculty of Medicine, Kagawa University, Kagawa, Japan. 4. Department of Hygiene, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Abstract
OBJECTIVES: We examined the effect of biologic disease-modifying anti-rheumatic drugs on the time to pregnancy in patients with rheumatoid arthritis who hope to become mothers. Additionally, we evaluated adverse pregnancy outcomes and risk factors of these drugs. METHOD: We retrospectively investigated 25 pregnancies of 19 patients who were taking disease-modifying anti-rheumatic drugs. In 15 pregnancies, patients continued biologic disease-modifying anti-rheumatic drugs until conception (group A). In 10 pregnancies, patients discontinued biologic disease-modifying anti-rheumatic drugs and conventional synthetic disease-modifying anti-rheumatic drugs at the time of planning to conceive (group B). We used tumor necrosis factor inhibitors (certolizumab pegol and etanercept) for group A patients. RESULTS: The mean time to pregnancy was shorter in group A than in group B (5.9 ± 3.8 vs 11.0 ± 6.5 months, P = 0.04). The mean birth weight of newborns was lighter in group B than in group A (2446.5 ± 352.4 vs 2969.4 ± 459.9 g, P = 0.007). There were no significant differences in the rates of preterm birth, light-for-date, and premature rupture of the membranes between the groups. In patients with preterm birth or light-for-date newborns, the mean dose of corticosteroids during pregnancy was significantly higher compared with that in those with full-term birth or non-light-for-date newborns (P = 0.02, P < 0.01, respectively). CONCLUSIONS: In patients with rheumatoid arthritis who hope to conceive, continuing biologic disease-modifying anti-rheumatic drugs at the time of conception could shorten the time to pregnancy. Using biologic disease-modifying anti-rheumatic drugs before pregnancy does not affect abortion, preterm birth, light-for-date, and premature rupture of the membranes.
OBJECTIVES: We examined the effect of biologic disease-modifying anti-rheumatic drugs on the time to pregnancy in patients with rheumatoid arthritis who hope to become mothers. Additionally, we evaluated adverse pregnancy outcomes and risk factors of these drugs. METHOD: We retrospectively investigated 25 pregnancies of 19 patients who were taking disease-modifying anti-rheumatic drugs. In 15 pregnancies, patients continued biologic disease-modifying anti-rheumatic drugs until conception (group A). In 10 pregnancies, patients discontinued biologic disease-modifying anti-rheumatic drugs and conventional synthetic disease-modifying anti-rheumatic drugs at the time of planning to conceive (group B). We used tumor necrosis factor inhibitors (certolizumab pegol and etanercept) for group A patients. RESULTS: The mean time to pregnancy was shorter in group A than in group B (5.9 ± 3.8 vs 11.0 ± 6.5 months, P = 0.04). The mean birth weight of newborns was lighter in group B than in group A (2446.5 ± 352.4 vs 2969.4 ± 459.9 g, P = 0.007). There were no significant differences in the rates of preterm birth, light-for-date, and premature rupture of the membranes between the groups. In patients with preterm birth or light-for-date newborns, the mean dose of corticosteroids during pregnancy was significantly higher compared with that in those with full-term birth or non-light-for-date newborns (P = 0.02, P < 0.01, respectively). CONCLUSIONS: In patients with rheumatoid arthritis who hope to conceive, continuing biologic disease-modifying anti-rheumatic drugs at the time of conception could shorten the time to pregnancy. Using biologic disease-modifying anti-rheumatic drugs before pregnancy does not affect abortion, preterm birth, light-for-date, and premature rupture of the membranes.
Entities:
Keywords:
Biologic disease-modifying anti-rheumatic drugs; Conception; Light-for-date; Preterm birth; Rheumatoid arthritis; Time to pregnancy
Authors: M Nørgaard; H Larsson; L Pedersen; F Granath; J Askling; H Kieler; A Ekbom; H T Sørensen; O Stephansson Journal: J Intern Med Date: 2010-10 Impact factor: 8.989
Authors: Marianne Wallenius; Johan F Skomsvoll; Lorentz M Irgens; Kjell Å Salvesen; Bjorn Y Nordvåg; Wenche Koldingsnes; Knut Mikkelsen; Cecilie Kaufmann; Tore K Kvien Journal: Arthritis Rheum Date: 2011-06
Authors: L Park-Wyllie; P Mazzotta; A Pastuszak; M E Moretti; L Beique; L Hunnisett; M H Friesen; S Jacobson; S Kasapinovic; D Chang; O Diav-Citrin; D Chitayat; I Nulman; T R Einarson; G Koren Journal: Teratology Date: 2000-12
Authors: Edward E Winger; Jane L Reed; Sherif Ashoush; Sapna Ahuja; Tarek El-Toukhy; Mohamed Taranissi Journal: Am J Reprod Immunol Date: 2008-12-03 Impact factor: 3.886
Authors: Yaël A de Man; Johanna M W Hazes; Hugo van der Heide; Sten P Willemsen; Christianne J M de Groot; Eric A P Steegers; Radboud J E M Dolhain Journal: Arthritis Rheum Date: 2009-11
Authors: Hieronymus T W Smeele; Esther Röder; Annemarie G M G J Mulders; Eric A P Steegers; Radboud J E M Dolhain Journal: Ann Rheum Dis Date: 2022-07-11 Impact factor: 27.973